MaxCyte, Inc. (MXCT): Price and Financial Metrics
MXCT Price/Volume Stats
| Current price | $4.14 | 52-week high | $7.50 |
| Prev. close | $4.08 | 52-week low | $3.36 |
| Day low | $3.98 | Volume | 242,300 |
| Day high | $4.20 | Avg. volume | 544,379 |
| 50-day MA | $4.53 | Dividend yield | N/A |
| 200-day MA | $5.39 | Market Cap | 425.78M |
MXCT Stock Price Chart Interactive Chart >
MXCT POWR Grades
- Quality is the dimension where MXCT ranks best; there it ranks ahead of 53.68% of US stocks.
- The strongest trend for MXCT is in Stability, which has been heading down over the past 179 days.
- MXCT's current lowest rank is in the Growth metric (where it is better than 5.66% of US stocks).
MXCT Stock Summary
- MXCT's went public 1.82 years ago, making it older than merely 4.05% of listed US stocks we're tracking.
- With a price/sales ratio of 10.09, MAXCYTE INC has a higher such ratio than 89.6% of stocks in our set.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.13 for MAXCYTE INC; that's greater than it is for merely 10.29% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to MAXCYTE INC are SLGC, WISH, HLGN, VRAY, and OM.
- To check out MAXCYTE INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001287098.
MXCT Valuation Summary
- In comparison to the median Healthcare stock, MXCT's price/sales ratio is 100% higher, now standing at 10.2.
- Over the past 22 months, MXCT's price/sales ratio has gone down 52.6.
Below are key valuation metrics over time for MXCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MXCT | 2023-05-23 | 10.2 | 1.7 | -13.8 | -13.1 |
| MXCT | 2023-05-22 | 10.2 | 1.7 | -13.9 | -13.2 |
| MXCT | 2023-05-19 | 9.6 | 1.6 | -13.0 | -12.3 |
| MXCT | 2023-05-18 | 9.4 | 1.6 | -12.7 | -12.1 |
| MXCT | 2023-05-17 | 9.5 | 1.6 | -12.9 | -12.3 |
| MXCT | 2023-05-16 | 9.2 | 1.5 | -12.5 | -11.9 |
MaxCyte, Inc. (MXCT) Company Bio
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Latest MXCT News From Around the Web
Below are the latest news stories about MAXCYTE INC that investors may wish to consider to help them evaluate MXCT as an investment opportunity.
Earnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% DiveMaxCyte, Inc. ( LON:MXCT ) shareholders that were waiting for something to happen have been dealt a blow with a 28... |
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue EstimatesMaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 GuidanceROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, today announced financial results for the first quarter ended March 31, 2023, and updated 2023 revenue guidance. First Quarter Highlights Total revenue of $8.6 million in the fir |
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell PlatformWalking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseasesROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today annou |
MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this yearViewing insider transactions for MaxCyte, Inc.'s ( LON:MXCT ) over the last year, we see that insiders were net buyers... |
MXCT Price Returns
| 1-mo | -15.68% |
| 3-mo | -13.21% |
| 6-mo | -31.91% |
| 1-year | -8.00% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -24.18% |
| 2022 | -46.42% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...